// Biotech and Pharma Therapeutics
Novartis Ianalumab Significantly Extends Disease Control in Patients with Immune Thrombocytopenia with Only Four Once-Monthly Doses
December 9, 2025 / ianalumab ITP treatment / platelet count improvement / immune thrombocytopenia therapy / B-cell depletion drug / Novartis VAYHIT2 trial
Novartis’ ianalumab, combined with eltrombopag, significantly extended disease control and improved platelet response in immune thrombocytopenia (ITP) patients with just four monthly doses, offering a promising short-term therapy targeting B-cell–mediated platelet destruction.
Telehealth prescribers urge feds to act quickly on virtual Rx
December 9, 2025 / telehealth prescribing rules / DEA virtual care / controlled substance access / mental health telemedicine / ATA Action advocacy
Telehealth advocates urge swift DEA action to extend virtual prescribing flexibilities for controlled substances, warning that delays could disrupt care for millions, particularly those with mental health and chronic conditions reliant on remote medication access.
The Future of Pharma Marketing: How AI and Real-World Data Are Redefining Personalization
December 9, 2025 / AI AI pharma marketing / real-world data personalization / patient targeting precision / HCP engagement strategies / digital health advertising
AI and real-world data are transforming pharma marketing by enabling personalized, HIPAA-compliant outreach to patients and providers, improving treatment alignment, adherence, and therapeutic outcomes through predictive targeting across digital and traditional media channels.
How Lilly uses Big Pharma heft to lift up-and-coming biotechs
December 9, 2025 / Lilly ExploR&D program / biotech collaboration pharma / early-stage drug development / AI in R&D / Big Pharma innovation
Eli Lilly’s ExploR&D program leverages Big Pharma resources—AI, supercomputing, and clinical expertise—to support early-stage biotechs, accelerating drug development and fostering external innovation amid a challenging biotech funding environment.
Most of the world isn’t getting enough omega-3
December 9, 2025 / omega-3 deficiency global / EPA DHA nutrition / omega-3 intake guidelines / sustainable supplement access / essential fatty acids health
A global review reveals widespread omega-3 deficiency, stressing the essential roles of EPA and DHA across life stages. Researchers urge improved guidelines, supplementation access, and sustainable sourcing to close the dietary gap.
// 4th Industrial Revolution
HHS releases AI strategy for agency operations
December 9, 2025 / HHS AI strategy / federal health data / artificial intelligence infrastructure / CMS NIH integration / public health modernization
HHS released its “OneHHS” AI strategy to integrate artificial intelligence across internal operations, enhancing data infrastructure, research, and cybersecurity across agencies like NIH, FDA, and CMS, while fostering collaboration and efficiency without yet impacting direct service delivery.
Scientists reveal a tiny brain chip that streams thoughts in real time
December 9, 2025 / brain-computer interface / neural implant technology / real-time thought streaming / BISC chip neuroscience / paralysis epilepsy blindness
The BISC neural implant enables real-time brain-to-computer communication via a high-bandwidth wireless chip, offering promising applications in treating paralysis, epilepsy, and blindness through precise decoding of movement, perception, and intent.
Cabrini ED care wraps 24 minutes earlier using AI scribe
December 9, 2025 / AI scribe emergency care / clinical documentation efficiency / Cabrini Health Heidi / ED workflow optimization / digital health Australia
Cabrini Health’s ED cut care time by 24 minutes using Heidi Health’s AI scribe, improving documentation efficiency, clinician satisfaction, and patient experience without clinical compromise—highlighting AI’s growing role in emergency care workflows.
AI-driven method uncovers genetic interactions that fuel cancer progression
December 9, 2025 / AI cancer genetics / tumor gene networks / genetic interactions oncology / cancer progression mapping / precision oncology tools
University of South Australia researchers developed an AI-driven method that identifies gene networks—rather than individual mutations—driving cancer progression, revealing hidden contributors to tumor growth and enabling more precise, early-stage therapeutic targeting.
AI Perspectives and New AI Assistant with Don Woodlock from InterSystems
December 9, 2025 / AI in healthcare / InterSystems AI assistant / clinical decision support / ambient voice documentation / healthcare interoperability tools
InterSystems is advancing healthcare AI through ambient voice tools and a new AI assistant that queries patient records, enhancing clinician workflows, patient experience, and administrative efficiency—while emphasizing trust, accuracy, and interoperability across connected health systems.
// Business & Markets
Cogent Biosciences Announces Positive Top-line Results of APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)
December 8, 2025 / bezuclastinib AdvSM / APEX clinical trial / systemic mastocytosis treatment / KIT inhibitor therapy / Cogent Biosciences NDA
Bezuclastinib demonstrated rapid, durable responses and favorable tolerability in advanced systemic mastocytosis in the Phase III APEX trial, supporting its role as a selective KIT inhibitor and enabling a planned FDA submission in 2026.
Zocdoc Partners with Healthgrades to Help People Book Doctor’s Appointments
December 9, 2025 / Zocdoc Healthgrades partnership / real-time appointment booking / doctor finder integration / patient access healthcare / online provider scheduling
Zocdoc and Healthgrades have partnered to integrate real-time doctor appointment booking into Healthgrades’ provider directory, enhancing patient access, streamlining scheduling, and improving care continuity through a unified, insurance-compatible digital platform.
Why Welldoc’s Partnership with CLEAR is a Blueprint for the CMS Health Tech Ecosystem
December 9, 2025 / Welldoc CLEAR partnership / AI chronic care / CMS health tech ecosystem / identity verification healthcare / digital health data integration
Welldoc is partnering with CLEAR to integrate secure identity verification into its cardiometabolic care app, enabling seamless, CMS-aligned health data aggregation to power AI-driven chronic disease management and improve outcomes for patients with diabetes, obesity, and related conditions.
Teleflex Medical to Sell for $1.5B
December 9, 2025 / Teleflex OEM acquisition / catheter device manufacturing / structural heart technology / neurovascular electrophysiology urology / medical device private equity
Teleflex Medical OEM will be acquired for $1.5B by Montagu and Kohlberg, becoming an independent company focused on custom catheter technologies, with plans to accelerate innovation and growth in structural heart, neurovascular, electrophysiology, and urology markets.
PGxAI and Lean Business Services Partner to Scale AI Pharmacogenomics in Saudi Arabia
December 9, 2025 / AI pharmacogenomics Saudi / adverse drug reactions / precision medicine Saudi Arabia / Vision 2030 healthcare / genomic data sovereignty
PGxAI and Lean Business Services have partnered to deploy AI-powered pharmacogenomics across Saudi Arabia, integrating genomic insights into clinical care to reduce adverse drug reactions and support Vision 2030’s push toward data sovereignty and precision medicine leadership.
// Legal & Regulatory
First Approval in Commissioner’s National Priority Voucher Pilot Program Strengthens Domestic Antibiotic Manufacturing Capacity
December 9, 2025 / FDA antibiotic approval / domestic drug manufacturing / Augmentin XR shortage / CNPV pilot program / amoxicillin supply chain
The FDA approved Augmentin XR under the CNPV pilot program in just two months, boosting domestic antibiotic manufacturing and addressing national shortages of essential drugs like amoxicillin, while enhancing supply chain security and public health resilience.
FDA now has Merck, AZ and Sanofi RSV shots for infants in its crosshairs: Reuters
December 9, 2025 / RSV infant safety / FDA vaccine investigation / Beyfortus Enflonsia review / monoclonal antibody scrutiny / Merck Sanofi AstraZeneca
The FDA is investigating the safety of RSV monoclonal antibody shots from Merck, AstraZeneca, and Sanofi following increased scrutiny of vaccines and immunoprophylactics. Despite strong safety data, the review reflects broader shifts in U.S. vaccine oversight and public trust.
Once public, now private, Gamida Cell scores 2nd FDA nod for stem cell therapy Omisirge
December 9, 2025 / Omisirge FDA approval / stem cell therapy / severe aplastic anemia / Gamida Cell Ayrmid / hematopoietic recovery treatment
Gamida Cell’s Omisirge has received FDA approval for severe aplastic anemia, showing 86% hematopoietic recovery and 92% survival. The stem cell therapy offers a curative option for high-risk patients lacking matched donors, with no severe GVHD reported.
Agios Pharma stock awaits FDA decision on Pyrukynd as PDUFA date passes
December 9, 2025 / Pyrukynd thalassemia approval / Agios FDA decision / mitapivat sNDA review / rare blood disorder treatment / PDUFA date delay
Agios Pharma’s FDA decision for Pyrukynd (mitapivat) in treating thalassemia remains pending past the PDUFA date. The agency is finalizing labeling and REMS, with no additional efficacy or safety data requested, keeping approval prospects intact.
FDA set to raise bar for clinical trials of CAR-T therapies
December 9, 2025 / CAR-T therapies / FDA clinical trials / randomized controlled trials / oncology drug approval / cell therapy regulations
The FDA will now require randomized controlled trials (RCTs) with survival-based endpoints for most CAR-T therapies, replacing single-arm studies to ensure clearer efficacy, though flexibility remains for rare cancers and relapsed cases.
// Research & Development
Simple light trick reveals hidden brain pathways in microscopic detail
December 9, 2025 / ComSLI imaging / brain microstructure / Alzheimer’s research / fiber orientation mapping / tissue microscopy
ComSLI, a new imaging method using rotating LED light and basic microscopy, reveals detailed fiber orientations in tissues, enabling deeper study of brain pathways and microstructural changes in diseases like Alzheimer’s across both fresh and historical samples.
BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
December 9, 2025 / pumitamig trial / triple-negative breast cancer / bispecific antibody therapy / PD-L1 VEGF-A / oncology clinical data
Pumitamig, a PD-L1xVEGF-A bispecific antibody, showed promising efficacy and manageable safety in advanced triple-negative breast cancer, including PD-L1–negative cases, supporting ongoing Phase 3 trials and potential broad use across solid tumors.
Highly sensitive CRISPR-based method designed to detect low-frequency cancer mutations
MUTE-Seq, a CRISPR-based method using high-fidelity FnCas9-AF2, enables ultra-sensitive detection of low-frequency cancer mutations in liquid biopsies, enhancing early diagnosis, MRD monitoring, and treatment response tracking with improved accuracy and reduced sequencing noise.
Five-year study confirms durable efficacy of etranacogene dezaparvovec
December 9, 2025 / etranacogene dezaparvovec / haemophilia B gene therapy / HOPE-B trial / factor IX durability / bleeding disorder treatment
Five-year HOPE-B data confirm that a single infusion of etranacogene dezaparvovec offers durable factor IX expression and significant bleed reduction in adults with haemophilia B, reinforcing its safety and long-term efficacy as a transformative gene therapy.
Gene therapy spurs improvement in rare neuromuscular disease
December 9, 2025 / spinal muscular atrophy / SMA gene therapy / neuromuscular disease treatment / pediatric gene replacement / motor function improvement
A Nature Medicine study shows single-dose gene replacement therapy significantly improved motor function in children and adolescents with spinal muscular atrophy, with comparable safety to controls, highlighting gene therapy as a potential alternative to chronic treatment.
// Politics
US sets to vote on controversial bill curbing China biotech investment; move will undermine global tech cooperation, hurt US firms: analysts
December 9, 2025 / biotech investment ban / China biotech restrictions / US NDAA 2025 / Biosecure Act impact / global biotech collaboration
The 2025 NDAA may restrict U.S. investment in Chinese biotech and ban federal contracts with targeted firms, potentially disrupting global biotech collaboration, raising innovation costs, and sidelining U.S. companies in the world’s largest healthcare growth market.
The Impact of Vaccine Policy Shifts on Public Health and Biotech Markets
December 6, 2025 / vaccine policy impact / mRNA biotech shift / FDA vaccine regulations / oncology drug development / biotech market trends
U.S. vaccine policy changes from 2023–2025 disrupted biotech markets, reducing mRNA funding and increasing regulatory hurdles, prompting firms like Moderna and BioNTech to pivot toward oncology and rare disease applications for long-term stability and innovation.
Healthcare lobbying surged in 2025
December 4, 2025 / healthcare lobbying 2025 / policy influence healthcare / Capitol Hill health policy / healthcare regulation trends / industry lobbying surge
Despite legislative setbacks, 2025 saw a surge in healthcare lobbying activity as industry groups increased efforts to influence policy amid regulatory pressures, reimbursement challenges, and shifting federal priorities.
Are RSV shots next in line for restrictions in the US?
December 10, 2025 / RSV vaccine review / infant antibody safety / FDA Beyfortus Enflonsia / pediatric vaccine policy / RSV hospitalization reduction
The FDA is reviewing the safety of infant RSV antibodies Beyfortus and Enflonsia, raising concerns of potential restrictions amid political shifts in vaccine policy, despite evidence showing significant reductions in RSV-related hospitalizations and strong efficacy data.
States battle for rural health funding
December 8, 2025 / rural health funding / state health policy / CMS rural program / telehealth expansion US / healthcare access rural
States are competing for shares of a $50B rural health fund by pledging policy changes tied to White House priorities, including telehealth expansion and nutrition restrictions, raising concerns about politicization and long-term feasibility of healthcare reform.